Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 11/20 | 0.41 |
| ▸ | HTR2C | P28335 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25561682 | 0.88 | MDM2 (0.54) | CYP2D6SLC6A2SLC6A4SLC6A3MDM2 | |
| SCHEMBL11958085 | 0.79 | HTR2C (0.53) | CYP2D6SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL11958228 | 0.79 | HTR2C (0.53) | CYP2D6SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL11957710 | 0.79 | HTR2C (0.53) | CYP2D6SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL11958335 | 0.76 | HTR3A (0.49) | CYP2D6SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL38662188 | 0.73 | SLC6A2 (0.43) | CYP2D6SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL2253446 | 0.72 | CYP2D6 (0.79) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11958758 | 0.72 | HTR2C (0.46) | CYP2D6HTR2CHTR2AHTR2B | |
| SCHEMBL11958801 | 0.72 | HTR2C (0.46) | CYP2D6HTR2CHTR2AHTR2B | |
| SCHEMBL11958220 | 0.72 | HTR2C (0.49) | CYP2D6HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | CYP2D6 1031/4885SLC6A2 1000/4885SLC6A4 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.